<DOC>
	<DOCNO>NCT02151708</DOCNO>
	<brief_summary>Functional dyspepsia ( FD ) disorder characterize chronic recurrent upper abdominal pain discomfort absence specific structural cause.1 Several mechanism suggest underlie dyspeptic symptom . In barostat study Tack et al.2 , impaired gastric accommodation meal find 40 % patient FD , abnormality associate early satiety . Delayed gastric emptying ( GE ) also find almost 40 % patient FD , associate symptom postprandial fullness , vomit early satiety.3-5 Improving gastric accommodation prokinetic effect seem attractive physiological target patient FD . Motilitone ( Dong-A ST , Yongin , Korea ) new herbal drug launch December 2011 Korea treat patient FD . It multiple mechanisms action fundus relaxation , visceral analgesia prokinetic effects.6 The current study aim evaluate effect motilitone gastric empty accommodation meal patient FD use three-dimensional gastric volume measurement magnetic resonance imaging ( MRI ) . Patients randomly allocate receive either motilitone 90 mg daily , motilitone 180 mg daily placebo double blind manner . After 2 week treatment , patient undergo gastric MRI . The primary endpoint gastric empty rate . The secondary endpoint gastric accommodation symptom improvement .</brief_summary>
	<brief_title>Efficacy Motilitone Gastric Emptying Patients With Functional Dyspepsia : Evaluation Using MRI Method</brief_title>
	<detailed_description>Same</detailed_description>
	<mesh_term>Dyspepsia</mesh_term>
	<criteria>1 . 20 70 year age 2 . Diagnosed functional dyspepsia patient ROME III diagnostic criterion 3 . Symptom score threepoint 8 kind symptom NDIK table 4 . Signed write informed consent . 1 . Any functional GI diease 2 . Previous abdominal surgery 3. pregnancy lactation 4 . Other condition likely interfere study procedure . judge investigator 5 . Allergic history motilitone 6 . Contraindications MRI 7 . Significant cardiopulmonary disease 8 . Significant renal ( serum creatinine level≥1.5 x upper normal limit ) liver ( AST ALT≥2.5xULN ) disease 9 . Can stop take medication gastric motility booster antacid prior start study 10 . Uncontrollable diabetes mellitus ( HbA1C &gt; 7 % ) 11 . Any malignancy within 5 year prior start study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>accommodation , empty , motilitone</keyword>
</DOC>